The IASLC 2023 World Conference on Lung Cancer (WCLC) is scheduled to be held in Singapore from September 9 - 12, 2023. During this conference, Hansoh Pharma will unveil 42 innovative findings related to AMEILE (Aumolertinib Mesylate tablets）, reflecting high recognition from the international oncology community of China's original research and innovation.

WCLC is the world's largest multidisciplinary oncology conference focused on lung cancer. Previous conferences have witnessed the announcement of numerous significant clinical research findings, which subsequently improve clinical practice. It serves as a "barometer" to keep up with research advancements in the global lung cancer field.

As the first domestically developed third-generation EGFR-TKI  by Hansoh Pharma, AMEILE garners international recognition due to its outstanding efficacy and safety. The number of related results published in SCI journals or at international conferences has already exceeded 100. To further explore the therapeutic potential of AMEILE in specific areas of lung cancer and benefit more patients with non-small cell lung cancer (NSCLC), clinical trials for additional indications are being accelerated, including the use of AMEILE for adjuvant therapy in EGFR-mutated NSCLC, as well as for combination therapy with platinum-based chemotherapy as a first-line treatment in EGFR-mutated NSCLC. The ultimate aim is to provide NSCLC patients with comprehensive, multi-dimensional drug regimens, covering from early to advanced stages of the disease, as well as perioperative therapy to first-line and subsequent treatments.

At this year's WCLC, the 42 publications on AMEILE include 3 oral/ mini-oral presentations, 39 posters/ E-posters. These publications will showcase the latest research progress of AMEILE in areas of combination therapy, brain (leptomeningeal) metastasis, early-stage therapy, patient subset, safety, and quality of life.   Oral/ Mini Oral 3 1. Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study Session Type: Oral, number: OA03.03 Corresponding author: Sun yat-sen university cancer center, Guangzhou/CN, L.K. Chen First author: Sun yat-sen university cancer center, Guangzhou/CN, J. Chen Date: September 10, 2023, 12:32-12:42 (SGT)   2. Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study Session Type: Mini Oral, Number: MA13.05 Corresponding author: West China Hospital, Sichuan University, Chengdu/CN, M.J. Huang First author: West China Hospital, Sichuan University, Chengdu/CN, M. Yu Date: September 11, 2023, 15:57-16:02 (SGT)   3. Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS) Session Type: Workshop/Oral, Number: WS02.12/P2.09-32 First author: Affiliated Hospital of Guangdong Medical University, Zhanjiang/CN, H.l. Chen Date: September 9, 2023, 10:40-10:50 (SGT)   Poster/E-Poster 39 1. Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT) Session Type: Poster, Number: P1.27-09 Author: Shanghai Jiao Tong University affiliated Chest Hospital, Shanghai/CN, B.H. Han   2. Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer Session Type: Poster, Number: P2.09-06 Author: Beijing Cancer Hospital, Beijing/CN, J. Fang   3. Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated Session Type: Poster, Number: P2.09-07 Author: Sun Yat-sen University Cancer Center, Guangzhou/CN, W.F. Fang   4. Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles Session Type: Poster, Number: P2.09-16 Author: Cancer Center, Chongqing University Three Gorges Hospital, Chongqing/CN, W. Wang   5. Increased Dose of Aumolertinib Rechallenge in Advanced NSCLC with Gradual Progression Session Type: Poster, Number: P2.09-19 Author: China-Japan Union Hospital of Jilin University/third Hospital of Jilin University, Changchun/CN, J. Li   6. Efficacy of Aumolertinib in EGFR T790M-negative or -unknown NSCLC with Brain Metastases Following Resistance to Prior EGFR-TKIs Session Type: Poster, Number: P2.09-22 Author: ShengJing Hospital of China Medical University, Shenyang/CN, C.B. Han   7. Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy Session Type: Poster, Number: P2.09-42 Author:  The second affiliated hospital of Harbin Medical University, Harbin/CN, L. Li   8 Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions Session Type: E-Poster, Number: EP07.05-05 Author: Dushu Lake Hospital Affiliated to Soochow Univesity, Suzhou/CN, H.T. Ma   9. Efficacy and safety of adjuvant aumolertinib in stage IB-IIIA NSCLC after R0 resection and the correlation between efficacy and postoperative MRD status Session Type: E-Poster, Number: EP07.05-10 Author: The first people's hospital of foshan, Foshan/CN, S.L. Yang   10. HRQoL with Adjuvant Aumolertinib in Patients with Resected Stage IB-IIIA EGFR Mutant Non-Small Cell Lung Cancer Session Type: E-Poster, Number: EP07.05-14 Author: Zhongnan Hospital of Wuhan University, Wuhan/CN, W.D. Hu   11. Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial Session Type: E-Poster, Number: EP07.05-17 Author: Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai/CN, W.T. Fang     12. The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study Session Type: E-Poster, Number: EP12.01-01 Author: The First Affiliated Hospital of Nanchang University, Nanchang/CN, L.H. Sun   13. First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases Session Type: E-Poster, Number: EP12.01-14 Author: The Second Hospital of Tianjin Medical, Tianjin/CN, L. Zang   14. Aumolertinib Combination SBRT Treated EGFR Co-mutation Patients with Symptomatic Brain Metastases: A Case Report Session Type: E-Poster, Number: EP12.01-15 Author: The affiliated hospital of Zhengzhou university, Henan Cancer Hospital, Zhengzhou/CN, X.J. Zhang   15. The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment Session Type: E-Poster, Number: EP12.01-16 Author: Quzhou People’s Hospital, Quzhou/CN, Q.H. Zheng   16. Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib Session Type: E-Poster, Number: EP12.01-19 Author: Sir Run Run Shaw Hospital, Hangzhou/CN, E. G. Chen   17. A Case of Brain Metastases from Lung Cancer with Epilepsy and ECOG Score of 4 Successfully Treated with Aumolertinib Session Type: E-Poster, Number: EP12.01-21 Author: Beijing Tsinghua Changgung Hospital, Beijing/CN, J.Q. Zhao   18. High-Dose Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC with Meningeal Symptoms as the First Symptom Session Type: E-Poster, Number: EP12.01-24 Author: Cancer Center, Chongqing University Three Gorges Hospital, Chongqing/CN, W. Wang   19. Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results Session Type: E-Poster, Number: EP12.01-25 Author: Nanjing Chest hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing/CN, S.C. Fang   20. Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations Session Type: E-Poster, Number: EP12.01-26 Author: Nanjing Chest hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing/CN, S.C. Fang   21. A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis Session Type: E-Poster, Number: EP12.01-28 Author: The first affiliated hospital of dalian medical university, Dalian/CN, X. Shan   22. Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib Session Type: E-Poster, Number: EP12.01-29 Author: Cancer Hospital Chinese Academy of Medical Sciences, Beijing/CN, J.C. Duan   23. Intracranial Complete Remissions and Long-Term Response in a EGFR positive NSCLC Patient with Brain Metastases: Case Report Session Type: E-Poster, Number: EP12.01-32 Author: Guangzhou panyu central hospital, Guangzhou/CN, H.R. Su   24. Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations Session Type: E-Poster, Number: EP12.01-37 Author: The First Affiliated Hospital of Bengbu Medical College, Bengbu/CN, T. Tao   25. The Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastasess Session Type: E-Poster, Number: EP12.01-40 Author: Shandong Cancer Hospital and Institute, Jinan/CN, Q. Shao   26. Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib Session Type: E-Poster, Number: EP12.01-44 Author: Xijing Hospital of Air Force Military Medical University, Xi'an/CN, Y. Chen   27. Real-World Outcomes of Health-Related Quality-of-Life (HRQoL) In Advanced Non-small Cell Lung Cancer Patients Treated with Aumolertinib Session Type: E-Poster, Number: EP12.01-45 Author: Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan/CN, J. S. Li   28. A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases Session Type: E-Poster, Number: EP12.01-48 Author: The affiliated hospital of Zhengzhou university, Henan Cancer Hospital, Zhengzhou/CN, H.J. Wang   29. Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE) Session Type: E-Poster, Number: EP12.01-55 Author: Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou/CN, G. Lin   30. Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases Session Type: E-Poster, Number: EP12.01-56 Author: The First Affiliated Hospital of Xia‘men University, Xia'men/CN, Y.B. Li   31. Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report Session Type: E-Poster, Number: EP12.01-57 Author: Affiliated Hospital of Zunyi Medical University, Zunyi/CN, C. Chen   32. Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment Session Type: E-Poster, Number: EP12.01-58 Author: West China Hospital, Sichuan University, Chengdu/CN, Q. Wu   33. Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study Session Type: E-Poster, Number: EP12.01-63 Author: Tongren City People's Hospital, Tongren/CN, B. Yao   34. Long Survival in LM NSCLC Treated with Aumolertinib and Metronomic Intrathecal Pemetrexed under Dynamic Detection of CSF ctDNA Session Type: E-Poster, Number: EP12.01-66 Author: The Second Affiliated Hospital of Dalian Medical University, Dalian/CN, Z.X. Dai   35. Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases Session Type: E-Poster, Number: EP12.01-68 Author: The First Affiliated Hospital of Anhui Medical University, Hefei/CN, Q.Q. Zhu   36. Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure Session Type: E-Poster, Number: EP12.01-71 Author: Nanjing Chest hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing/CN, S.C. Fang   37. Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results Session Type: E-Poster, Number: EP12.01-72 Author: Nanjing Chest hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing/CN, S.C. Fang   38. Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy Session Type: E-Poster, Number: EP12.01-73 Author: West China Hospital, Sichuan University, Chengdu/CN, F. Luo   39. Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area Session Type: E-Poster, Number: EP12.01-77 Author: The First Affiliated Hospital of Kunming Medical University, Kun Ming/CN, J.Q. Zhang   The details 2023 WCLC abstract title of the Aumolertinib can be found at the following link: //cattendee.abstractsonline.com/meeting/10925?view=appendToCards&initialSearchId=3&searchId=3